Verrica Pharmaceuticals Inc. (VRCA)
$
0.54
-0.03 (-5.56%)
Key metrics
Financial statements
Free cash flow per share
-0.5661
Market cap
49.9 Million
Price to sales ratio
6.9545
Debt to equity
-0.7873
Current ratio
1.3428
Income quality
0.8131
Average inventory
2.5 Million
ROE
3.4829
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing and commercializing treatments for skin diseases in the United States. The company’s lead product candidate, VP-102, is aimed at treating molluscum contagiosum and has already completed a Phase II clinical trial for the treatment of external genital warts, while also advancing into Phase II clinical trials for common warts. Additionally, Verrica is working on a cantharidin-based product, VP-103, intended for the treatment of plantar warts. The EBITDA ratio is -8.71 highlighting the company’s operational efficiency, and its total costs and expenses amount to $73,485,000.00 reflecting its overall spending. With an income before tax ratio of -10.12 the company demonstrates a noteworthy pre-tax margin. Notably, Verrica achieved a revenue of $7,566,000.00 indicating its niche market focus, alongside a diluted EPS of -$1.48 which accounts for potential share dilution. Verrica also maintains a strategic partnership through a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates targeting molluscum contagiosum and common warts in Japan, including VP-102, as well as a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Founded in 2013, the company is headquartered in West Chester, Pennsylvania. The stock is affordable at $0.54 making it suitable for budget-conscious investors looking for opportunities in the market. Additionally, the stock has an average trading volume of 402,755.00 indicating moderate liquidity, which is beneficial for those interested in trading. With a market capitalization of $49,926,642.00 the company is classified as a small-cap player, reflecting its size and potential for growth within the market. Verrica Pharmaceuticals Inc. is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and fulfilling an essential role in the advancement of dermatological treatments. Furthermore, it belongs to the Healthcare sector, driving innovation and growth while addressing unmet medical needs in the treatment of skin diseases.
Is Verrica Pharmaceuticals Inc. (VRCA) a good investment?
Investing in Verrica Pharmaceuticals Inc. (VRCA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Verrica Pharmaceuticals Inc. (VRCA)'s stock forecast?
Analysts predict Verrica Pharmaceuticals Inc. stock to fluctuate between $0.38 (low) and $9.36 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Verrica Pharmaceuticals Inc.'s market capitalization?
As of 2025-05-29, Verrica Pharmaceuticals Inc.'s market cap is $49,926,642, based on 92,491,000 outstanding shares.
How does Verrica Pharmaceuticals Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Verrica Pharmaceuticals Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Verrica Pharmaceuticals Inc. (VRCA) stock?
To buy Verrica Pharmaceuticals Inc. (VRCA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for VRCA. Place an order (Market, Limit, etc.).
What is the best time to invest in Verrica Pharmaceuticals Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Verrica Pharmaceuticals Inc. perform in the last earnings report?
Revenue: $7,566,000 | EPS: -$1.48 | Growth: -0%.
Where can I find Verrica Pharmaceuticals Inc.'s investor relations reports?
Visit https://www.verrica.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Verrica Pharmaceuticals Inc.?
You can explore historical data from here
What is the all-time high and low for Verrica Pharmaceuticals Inc. stock?
All-time high: $18.42 (2021-03-11) | All-time low: $0.38 (2025-04-03).
What are the key trends affecting Verrica Pharmaceuticals Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
2 days ago
WEST CHESTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference in New York City.
seekingalpha.com
16 days ago
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA ) Q1 2025 Corporate Update Conference Call May 13, 2025 4:30 PM ET Company Participants Kevin Gardner - Managing Director LifeSci Advisors Jayson Rieger - President and CEO John Kirby - Interim CFO Conference Call Participants Stacy Ku - TD Cowen Gregory Renza - RBC Capital Markets Serge Belanger - Needham and Company Kemp Dolliver - Brookline Capital Markets Operator Good evening, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals' First Quarter 2025 Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
zacks.com
16 days ago
Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.38 per share a year ago.
globenewswire.com
16 days ago
– Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarter, the most in company history and a 16.7% growth over Q4'24 – – Late-stage pipeline continues to advance with completion of end-of-Phase 2 meeting with Food and Drug Administration for VP-315, Verrica's candidate for basal cell carcinoma, and continued advancement towards initiation of global Phase 3 program in common warts (VP-102/YCANTH) with partner Torii Pharmaceutical – – Conference call scheduled for today at 4:30 pm ET – WEST CHESTER, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced financial results for the quarter ended March 31, 2025.
globenewswire.com
23 days ago
WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m.
globenewswire.com
a month ago
WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Citizens Life Sciences Conference in New York City.
globenewswire.com
2 months ago
WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Gavin Corcoran, M.D.
zacks.com
2 months ago
Verrica Pharmaceuticals (VRCA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
globenewswire.com
2 months ago
WEST CHESTER, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference.
globenewswire.com
2 months ago
WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Noah L. Rosenberg, M.D., as Chief Medical Officer.
See all news
